Lorna Moore
Concepts (451)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Altitude | 84 | 2024 | 462 | 13.970 |
Why?
| Uterine Artery | 17 | 2024 | 78 | 5.840 |
Why?
| Fetal Growth Retardation | 33 | 2024 | 549 | 5.500 |
Why?
| Pre-Eclampsia | 17 | 2024 | 187 | 4.670 |
Why?
| Hypoxia | 39 | 2024 | 1087 | 4.110 |
Why?
| Fetal Hypoxia | 12 | 2024 | 54 | 4.050 |
Why?
| Pregnancy | 76 | 2024 | 6423 | 3.460 |
Why?
| Uterus | 15 | 2020 | 207 | 3.270 |
Why?
| Acclimatization | 20 | 2019 | 166 | 3.260 |
Why?
| Altitude Sickness | 18 | 2022 | 141 | 2.690 |
Why?
| Fetal Development | 9 | 2024 | 287 | 2.430 |
Why?
| Placenta | 15 | 2023 | 716 | 2.210 |
Why?
| Birth Weight | 23 | 2024 | 505 | 2.200 |
Why?
| Placental Circulation | 9 | 2024 | 65 | 2.180 |
Why?
| AMP-Activated Protein Kinases | 7 | 2024 | 190 | 2.040 |
Why?
| Vasodilation | 10 | 2022 | 476 | 1.970 |
Why?
| Hypertension, Pregnancy-Induced | 5 | 2023 | 67 | 1.940 |
Why?
| Arteries | 10 | 2022 | 266 | 1.930 |
Why?
| Oxygen | 17 | 2023 | 916 | 1.910 |
Why?
| Adaptation, Physiological | 12 | 2021 | 521 | 1.830 |
Why?
| Bolivia | 20 | 2024 | 63 | 1.660 |
Why?
| Vasoconstriction | 5 | 2015 | 199 | 1.430 |
Why?
| Regional Blood Flow | 10 | 2024 | 463 | 1.270 |
Why?
| Middle Cerebral Artery | 2 | 2024 | 43 | 1.110 |
Why?
| Selection, Genetic | 8 | 2019 | 252 | 1.060 |
Why?
| Female | 100 | 2024 | 68829 | 1.050 |
Why?
| Nitric Oxide Synthase | 4 | 2019 | 237 | 1.040 |
Why?
| Myometrium | 2 | 2020 | 37 | 1.040 |
Why?
| Fertility | 2 | 2021 | 156 | 0.940 |
Why?
| Endothelium, Vascular | 4 | 2019 | 902 | 0.920 |
Why?
| Oxygen Consumption | 15 | 2012 | 672 | 0.910 |
Why?
| Biological Evolution | 5 | 2015 | 435 | 0.860 |
Why?
| HELLP Syndrome | 1 | 2023 | 6 | 0.860 |
Why?
| Hemodynamics | 9 | 2024 | 1094 | 0.820 |
Why?
| Adult | 59 | 2024 | 35634 | 0.790 |
Why?
| Vascular Resistance | 7 | 2024 | 371 | 0.760 |
Why?
| Tibet | 14 | 2021 | 27 | 0.760 |
Why?
| Infant, Newborn | 23 | 2024 | 5772 | 0.740 |
Why?
| Humans | 105 | 2024 | 129847 | 0.730 |
Why?
| Pregnancy, Animal | 4 | 2006 | 53 | 0.730 |
Why?
| Muscle, Smooth, Vascular | 2 | 2019 | 444 | 0.720 |
Why?
| Gestational Age | 11 | 2024 | 876 | 0.700 |
Why?
| Hemoglobins | 8 | 2017 | 339 | 0.700 |
Why?
| Exercise | 8 | 2018 | 1934 | 0.680 |
Why?
| Pregnancy Outcome | 4 | 2019 | 392 | 0.670 |
Why?
| Pregnancy-Associated Plasma Protein-A | 1 | 2020 | 14 | 0.660 |
Why?
| Adrenergic alpha-Antagonists | 4 | 2003 | 33 | 0.640 |
Why?
| Pregnancy Complications | 6 | 2017 | 494 | 0.620 |
Why?
| Polycythemia | 3 | 2017 | 21 | 0.620 |
Why?
| Maternal-Fetal Exchange | 4 | 2021 | 162 | 0.600 |
Why?
| Protein Kinases | 1 | 2020 | 318 | 0.580 |
Why?
| Maternal Health Services | 1 | 2019 | 92 | 0.560 |
Why?
| Catecholamines | 8 | 2003 | 96 | 0.520 |
Why?
| Menstrual Cycle | 7 | 2003 | 121 | 0.500 |
Why?
| Infant, Small for Gestational Age | 3 | 2011 | 84 | 0.490 |
Why?
| Women's Health | 2 | 2011 | 364 | 0.480 |
Why?
| Nitric Oxide | 4 | 2020 | 896 | 0.480 |
Why?
| Fetus | 5 | 2023 | 782 | 0.450 |
Why?
| Pulmonary Circulation | 2 | 2021 | 431 | 0.450 |
Why?
| Receptor, Endothelin A | 1 | 2014 | 63 | 0.450 |
Why?
| Diabetes, Gestational | 1 | 2018 | 308 | 0.440 |
Why?
| Aromatase | 1 | 2014 | 31 | 0.440 |
Why?
| Genetics, Population | 6 | 2010 | 200 | 0.430 |
Why?
| Blood Pressure | 11 | 2020 | 1736 | 0.410 |
Why?
| Polymorphism, Single Nucleotide | 10 | 2019 | 2062 | 0.410 |
Why?
| Endothelin-1 | 2 | 2020 | 180 | 0.410 |
Why?
| Ultrasonography, Doppler | 3 | 2020 | 118 | 0.400 |
Why?
| Indians, South American | 6 | 2015 | 24 | 0.390 |
Why?
| PPAR gamma | 3 | 2020 | 183 | 0.390 |
Why?
| Estrogens | 2 | 2014 | 348 | 0.390 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 72 | 0.390 |
Why?
| Respiratory Mechanics | 4 | 2007 | 65 | 0.390 |
Why?
| Phenylephrine | 6 | 2020 | 75 | 0.390 |
Why?
| Infant, Low Birth Weight | 2 | 2011 | 134 | 0.380 |
Why?
| Angiotensin II | 2 | 2011 | 95 | 0.380 |
Why?
| Sleep Apnea Syndromes | 1 | 2013 | 82 | 0.380 |
Why?
| Guinea Pigs | 8 | 2006 | 157 | 0.380 |
Why?
| Young Adult | 12 | 2024 | 12467 | 0.380 |
Why?
| Health Services Accessibility | 1 | 2019 | 903 | 0.370 |
Why?
| Gene Frequency | 5 | 2014 | 500 | 0.370 |
Why?
| Receptor, Angiotensin, Type 2 | 1 | 2011 | 9 | 0.360 |
Why?
| Travel | 1 | 2012 | 122 | 0.360 |
Why?
| Enzymes | 1 | 2011 | 67 | 0.360 |
Why?
| Genome, Human | 4 | 2012 | 393 | 0.360 |
Why?
| Homeostasis | 2 | 2014 | 605 | 0.350 |
Why?
| Prazosin | 5 | 2003 | 23 | 0.350 |
Why?
| Angiostatic Proteins | 1 | 2010 | 5 | 0.350 |
Why?
| Animals | 24 | 2023 | 35409 | 0.350 |
Why?
| Angiogenic Proteins | 1 | 2010 | 16 | 0.340 |
Why?
| Infant Mortality | 2 | 2021 | 106 | 0.340 |
Why?
| South America | 5 | 2017 | 58 | 0.340 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 3 | 2022 | 70 | 0.320 |
Why?
| Ultrasonography, Prenatal | 3 | 2024 | 276 | 0.300 |
Why?
| Interleukin-1beta | 1 | 2010 | 369 | 0.300 |
Why?
| Antioxidants | 1 | 2011 | 558 | 0.290 |
Why?
| Mountaineering | 2 | 2005 | 34 | 0.290 |
Why?
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2011 | 4 | 0.290 |
Why?
| Case-Control Studies | 6 | 2024 | 3384 | 0.280 |
Why?
| Heart Rate | 7 | 2015 | 804 | 0.280 |
Why?
| Chronic Disease | 9 | 2013 | 1724 | 0.270 |
Why?
| Europe | 4 | 2009 | 363 | 0.260 |
Why?
| Blood Flow Velocity | 4 | 2011 | 406 | 0.260 |
Why?
| Oxidative Stress | 1 | 2013 | 1264 | 0.260 |
Why?
| Vasoconstrictor Agents | 3 | 2020 | 127 | 0.250 |
Why?
| Cardiovascular Physiological Phenomena | 1 | 2005 | 42 | 0.250 |
Why?
| Acetylcholine | 2 | 2020 | 184 | 0.240 |
Why?
| Autonomic Nervous System | 1 | 2005 | 75 | 0.240 |
Why?
| Research | 2 | 2005 | 420 | 0.240 |
Why?
| Fetal Death | 2 | 2003 | 55 | 0.230 |
Why?
| Placental Insufficiency | 2 | 2023 | 112 | 0.220 |
Why?
| Cytokines | 2 | 2010 | 2022 | 0.220 |
Why?
| Epinephrine | 3 | 2001 | 141 | 0.220 |
Why?
| Umbilical Arteries | 1 | 2024 | 53 | 0.220 |
Why?
| Infant | 6 | 2021 | 9018 | 0.220 |
Why?
| Embryonic and Fetal Development | 2 | 2003 | 95 | 0.220 |
Why?
| Mammals | 2 | 2022 | 274 | 0.220 |
Why?
| Models, Genetic | 2 | 2007 | 592 | 0.220 |
Why?
| Norepinephrine | 3 | 2001 | 209 | 0.220 |
Why?
| Chi-Square Distribution | 2 | 2018 | 515 | 0.220 |
Why?
| Mice | 8 | 2021 | 16983 | 0.220 |
Why?
| Peru | 2 | 2021 | 54 | 0.220 |
Why?
| Parity | 2 | 2018 | 121 | 0.210 |
Why?
| Interleukin-6 | 2 | 2010 | 724 | 0.200 |
Why?
| Mining | 1 | 2003 | 14 | 0.200 |
Why?
| Amino Acids | 3 | 2023 | 487 | 0.200 |
Why?
| Cerebrovascular Circulation | 1 | 2024 | 228 | 0.200 |
Why?
| Speech Production Measurement | 1 | 2002 | 12 | 0.200 |
Why?
| Silver | 1 | 2003 | 34 | 0.200 |
Why?
| Receptors, Adrenergic, alpha-1 | 2 | 2001 | 43 | 0.200 |
Why?
| Speech Disorders | 1 | 2002 | 34 | 0.200 |
Why?
| In Vitro Techniques | 4 | 2011 | 1092 | 0.200 |
Why?
| Geography | 3 | 2011 | 189 | 0.200 |
Why?
| Regression Analysis | 3 | 2018 | 998 | 0.190 |
Why?
| Myoglobin | 1 | 2002 | 12 | 0.190 |
Why?
| Carbohydrate Metabolism | 2 | 2000 | 62 | 0.190 |
Why?
| Progesterone | 5 | 2003 | 245 | 0.190 |
Why?
| Vasodilator Agents | 2 | 2020 | 326 | 0.190 |
Why?
| Potassium Channels | 2 | 2022 | 149 | 0.190 |
Why?
| Erythropoiesis | 1 | 2001 | 51 | 0.190 |
Why?
| Trophoblasts | 2 | 2019 | 189 | 0.190 |
Why?
| Adrenergic alpha-Agonists | 4 | 2003 | 28 | 0.180 |
Why?
| Motor Skills | 1 | 2002 | 93 | 0.180 |
Why?
| Developing Countries | 1 | 2023 | 284 | 0.180 |
Why?
| Enzyme Inhibitors | 4 | 2012 | 827 | 0.180 |
Why?
| Gene Expression Regulation | 4 | 2021 | 2545 | 0.180 |
Why?
| Reproduction | 1 | 2003 | 198 | 0.180 |
Why?
| Male | 26 | 2019 | 63759 | 0.180 |
Why?
| Signal Transduction | 3 | 2024 | 4935 | 0.170 |
Why?
| Luteal Phase | 5 | 2001 | 44 | 0.170 |
Why?
| Aminoimidazole Carboxamide | 1 | 2020 | 11 | 0.170 |
Why?
| Pyrones | 1 | 2020 | 9 | 0.170 |
Why?
| Glycolysis | 2 | 2021 | 314 | 0.170 |
Why?
| Respiratory Physiological Phenomena | 1 | 2000 | 30 | 0.170 |
Why?
| Ribonucleotides | 1 | 2020 | 24 | 0.170 |
Why?
| Muscle Relaxation | 1 | 2000 | 20 | 0.170 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 118 | 0.170 |
Why?
| Genotype | 4 | 2014 | 1829 | 0.170 |
Why?
| Biphenyl Compounds | 1 | 2020 | 60 | 0.160 |
Why?
| Reproductive Health | 1 | 2021 | 83 | 0.160 |
Why?
| Hypertension, Pulmonary | 2 | 2022 | 1897 | 0.160 |
Why?
| Risk Factors | 5 | 2019 | 9801 | 0.160 |
Why?
| Genetic Markers | 3 | 2012 | 334 | 0.160 |
Why?
| Arterial Pressure | 2 | 2017 | 119 | 0.160 |
Why?
| Thiophenes | 1 | 2020 | 117 | 0.160 |
Why?
| Neovascularization, Physiologic | 1 | 2021 | 176 | 0.160 |
Why?
| Respiratory Function Tests | 3 | 2013 | 581 | 0.160 |
Why?
| Mice, Inbred C57BL | 5 | 2021 | 5468 | 0.160 |
Why?
| Hypoxia-Inducible Factor-Proline Dioxygenases | 2 | 2017 | 21 | 0.160 |
Why?
| Erythropoietin | 2 | 2017 | 88 | 0.160 |
Why?
| Biological Transport | 3 | 2019 | 405 | 0.150 |
Why?
| Blood Volume | 4 | 2007 | 61 | 0.150 |
Why?
| Adrenergic beta-Antagonists | 1 | 2001 | 321 | 0.150 |
Why?
| Health Promotion | 1 | 2005 | 718 | 0.150 |
Why?
| Blood Gas Analysis | 3 | 2007 | 73 | 0.150 |
Why?
| Follicular Phase | 5 | 2001 | 38 | 0.150 |
Why?
| Estradiol | 5 | 2003 | 494 | 0.150 |
Why?
| Adipose Tissue, White | 1 | 2018 | 37 | 0.150 |
Why?
| Glyburide | 1 | 1998 | 35 | 0.150 |
Why?
| Intraocular Pressure | 1 | 2000 | 299 | 0.150 |
Why?
| Delivery, Obstetric | 2 | 2011 | 136 | 0.150 |
Why?
| Maternal Age | 1 | 2018 | 125 | 0.150 |
Why?
| Sudden Infant Death | 1 | 1998 | 27 | 0.150 |
Why?
| Analysis of Variance | 3 | 2011 | 1291 | 0.150 |
Why?
| Body Weights and Measures | 2 | 2015 | 35 | 0.150 |
Why?
| Cohort Studies | 4 | 2020 | 5444 | 0.140 |
Why?
| DNA | 2 | 2006 | 1406 | 0.140 |
Why?
| Respiration | 3 | 2005 | 193 | 0.140 |
Why?
| Ethiopia | 1 | 2017 | 37 | 0.140 |
Why?
| Models, Biological | 4 | 2015 | 1724 | 0.140 |
Why?
| Physical Endurance | 2 | 2001 | 264 | 0.140 |
Why?
| Glucose | 2 | 2023 | 1003 | 0.140 |
Why?
| Placenta Growth Factor | 2 | 2022 | 24 | 0.130 |
Why?
| Vascular Diseases | 2 | 2017 | 240 | 0.130 |
Why?
| Ovariectomy | 1 | 1997 | 137 | 0.130 |
Why?
| Receptors, Erythropoietin | 1 | 2017 | 20 | 0.130 |
Why?
| Linear Models | 2 | 2014 | 822 | 0.130 |
Why?
| Cross-Sectional Studies | 4 | 2022 | 5085 | 0.130 |
Why?
| Time Factors | 8 | 2011 | 6550 | 0.130 |
Why?
| Pulmonary Gas Exchange | 2 | 2015 | 121 | 0.130 |
Why?
| Cardiovascular System | 1 | 2017 | 136 | 0.130 |
Why?
| Pregnancy Complications, Cardiovascular | 3 | 2007 | 78 | 0.120 |
Why?
| Vascular Endothelial Growth Factor A | 3 | 2023 | 528 | 0.120 |
Why?
| Adolescent | 5 | 2019 | 20451 | 0.120 |
Why?
| Lipid Metabolism | 1 | 2018 | 503 | 0.120 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 235 | 0.120 |
Why?
| Electrocardiography | 1 | 1998 | 613 | 0.120 |
Why?
| Multivariate Analysis | 1 | 2018 | 1501 | 0.110 |
Why?
| Incidence | 2 | 2018 | 2646 | 0.110 |
Why?
| Polymorphism, Genetic | 2 | 2012 | 636 | 0.110 |
Why?
| Double-Blind Method | 4 | 2003 | 1877 | 0.110 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2015 | 203 | 0.110 |
Why?
| Receptor, Endothelin B | 1 | 2014 | 50 | 0.110 |
Why?
| Severity of Illness Index | 1 | 2002 | 2739 | 0.110 |
Why?
| Receptors, Endothelin | 1 | 2014 | 50 | 0.110 |
Why?
| Retrospective Studies | 4 | 2022 | 14553 | 0.110 |
Why?
| Body Height | 2 | 2013 | 192 | 0.110 |
Why?
| Sex Characteristics | 5 | 2001 | 735 | 0.110 |
Why?
| Phenotype | 2 | 2023 | 3062 | 0.110 |
Why?
| Prenatal Exposure Delayed Effects | 2 | 2021 | 573 | 0.110 |
Why?
| Body Weight | 3 | 2007 | 947 | 0.100 |
Why?
| Gonadal Steroid Hormones | 1 | 2014 | 132 | 0.100 |
Why?
| Atmosphere Exposure Chambers | 2 | 2002 | 6 | 0.100 |
Why?
| Pregnancy Trimesters | 1 | 2012 | 16 | 0.100 |
Why?
| Brain | 1 | 2024 | 2677 | 0.100 |
Why?
| Genetic Association Studies | 1 | 2014 | 357 | 0.100 |
Why?
| Optic Atrophy, Hereditary, Leber | 1 | 2012 | 5 | 0.100 |
Why?
| NG-Nitroarginine Methyl Ester | 1 | 2012 | 48 | 0.100 |
Why?
| Pulmonary Artery | 2 | 2015 | 1097 | 0.100 |
Why?
| Hypertension | 3 | 2015 | 1242 | 0.100 |
Why?
| Indomethacin | 1 | 2012 | 79 | 0.100 |
Why?
| NADH Dehydrogenase | 1 | 2012 | 18 | 0.100 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2012 | 80 | 0.100 |
Why?
| Gene Regulatory Networks | 1 | 2014 | 280 | 0.100 |
Why?
| Reference Values | 4 | 2003 | 796 | 0.100 |
Why?
| Lactic Acid | 3 | 2023 | 304 | 0.100 |
Why?
| Age Factors | 2 | 2011 | 3161 | 0.090 |
Why?
| Prevalence | 1 | 2018 | 2564 | 0.090 |
Why?
| Polysomnography | 1 | 2013 | 178 | 0.090 |
Why?
| Colorado | 5 | 2019 | 4410 | 0.090 |
Why?
| Apgar Score | 1 | 2011 | 16 | 0.090 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2014 | 398 | 0.090 |
Why?
| Population Dynamics | 1 | 2012 | 138 | 0.090 |
Why?
| Atmospheric Pressure | 2 | 2001 | 23 | 0.090 |
Why?
| Potassium Chloride | 1 | 2011 | 39 | 0.090 |
Why?
| Nitroarginine | 2 | 2002 | 57 | 0.090 |
Why?
| Laser-Doppler Flowmetry | 1 | 2011 | 33 | 0.090 |
Why?
| Middle Aged | 5 | 2019 | 31177 | 0.090 |
Why?
| Live Birth | 1 | 2011 | 57 | 0.090 |
Why?
| DNA, Mitochondrial | 1 | 2012 | 190 | 0.090 |
Why?
| Iliac Artery | 1 | 2011 | 55 | 0.090 |
Why?
| Stillbirth | 1 | 2011 | 60 | 0.090 |
Why?
| DNA Methylation | 1 | 2015 | 606 | 0.090 |
Why?
| Child Development | 1 | 2015 | 459 | 0.090 |
Why?
| Confidence Intervals | 1 | 2011 | 318 | 0.080 |
Why?
| Disease Models, Animal | 4 | 2021 | 4077 | 0.080 |
Why?
| Ultrasonography | 1 | 2014 | 713 | 0.080 |
Why?
| Pregnancy Proteins | 1 | 2010 | 36 | 0.080 |
Why?
| Alleles | 3 | 2012 | 843 | 0.080 |
Why?
| Sympathetic Nervous System | 2 | 2003 | 174 | 0.080 |
Why?
| Haplotypes | 3 | 2017 | 474 | 0.080 |
Why?
| Renal Circulation | 3 | 1998 | 57 | 0.080 |
Why?
| Anthropology, Physical | 1 | 2009 | 28 | 0.080 |
Why?
| Genomics | 2 | 2023 | 716 | 0.080 |
Why?
| Interleukin-4 | 1 | 2010 | 212 | 0.080 |
Why?
| Mesenteric Arteries | 2 | 2000 | 17 | 0.080 |
Why?
| Sheep | 2 | 2023 | 845 | 0.080 |
Why?
| Interleukin 1 Receptor Antagonist Protein | 1 | 2010 | 254 | 0.080 |
Why?
| Databases, Genetic | 1 | 2010 | 228 | 0.080 |
Why?
| Pedigree | 1 | 2010 | 483 | 0.080 |
Why?
| Lung Diseases | 1 | 2015 | 743 | 0.080 |
Why?
| Up-Regulation | 1 | 2011 | 836 | 0.080 |
Why?
| Ovary | 2 | 2018 | 209 | 0.070 |
Why?
| Interleukin-10 | 1 | 2010 | 304 | 0.070 |
Why?
| Basal Metabolism | 3 | 2003 | 58 | 0.070 |
Why?
| Transcription, Genetic | 1 | 2014 | 1416 | 0.070 |
Why?
| Exercise Test | 3 | 2001 | 614 | 0.070 |
Why?
| Lung | 1 | 2021 | 3940 | 0.070 |
Why?
| Heart Rate, Fetal | 1 | 2007 | 21 | 0.070 |
Why?
| Head | 1 | 2008 | 96 | 0.070 |
Why?
| Prospective Studies | 3 | 2022 | 7158 | 0.070 |
Why?
| Premature Birth | 1 | 2011 | 317 | 0.070 |
Why?
| Biometry | 1 | 2007 | 69 | 0.070 |
Why?
| Urban Health | 1 | 2007 | 79 | 0.070 |
Why?
| Aorta, Thoracic | 2 | 2000 | 263 | 0.070 |
Why?
| Indians, North American | 2 | 2009 | 601 | 0.070 |
Why?
| Health Status | 1 | 2011 | 758 | 0.060 |
Why?
| Femur | 1 | 2008 | 243 | 0.060 |
Why?
| Phylogeny | 2 | 2010 | 845 | 0.060 |
Why?
| Chromosome Mapping | 1 | 2007 | 499 | 0.060 |
Why?
| Respiratory Distress Syndrome, Newborn | 1 | 2007 | 103 | 0.060 |
Why?
| Serum | 1 | 2006 | 58 | 0.060 |
Why?
| Hypoxia-Inducible Factor 1 | 1 | 2006 | 72 | 0.060 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2010 | 1205 | 0.060 |
Why?
| Genetic Predisposition to Disease | 2 | 2012 | 2271 | 0.060 |
Why?
| Longitudinal Studies | 3 | 2019 | 2724 | 0.060 |
Why?
| Hyperplasia | 1 | 2006 | 175 | 0.060 |
Why?
| Cell Count | 1 | 2006 | 318 | 0.060 |
Why?
| Adrenergic alpha-1 Receptor Antagonists | 2 | 2001 | 17 | 0.060 |
Why?
| History, 21st Century | 1 | 2005 | 186 | 0.060 |
Why?
| Surveys and Questionnaires | 2 | 2011 | 5437 | 0.060 |
Why?
| Mental Health | 1 | 2011 | 691 | 0.060 |
Why?
| Gene-Environment Interaction | 2 | 2017 | 185 | 0.060 |
Why?
| History, 20th Century | 1 | 2005 | 295 | 0.060 |
Why?
| Child | 4 | 2015 | 20962 | 0.050 |
Why?
| Plasma Volume | 1 | 2003 | 19 | 0.050 |
Why?
| Cardiac Output | 3 | 1998 | 157 | 0.050 |
Why?
| Gene Expression Profiling | 1 | 2010 | 1686 | 0.050 |
Why?
| Pyruvates | 1 | 2023 | 24 | 0.050 |
Why?
| Lower Extremity | 1 | 2007 | 407 | 0.050 |
Why?
| Embryo Implantation | 1 | 2003 | 28 | 0.050 |
Why?
| Acute Disease | 2 | 2005 | 980 | 0.050 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 274 | 0.050 |
Why?
| History, 17th Century | 1 | 2003 | 14 | 0.050 |
Why?
| Primary Prevention | 1 | 2005 | 190 | 0.050 |
Why?
| Meclofenamic Acid | 1 | 2002 | 10 | 0.050 |
Why?
| Biomechanical Phenomena | 1 | 2006 | 766 | 0.050 |
Why?
| Ion Channels | 1 | 2023 | 133 | 0.050 |
Why?
| Glutamine | 1 | 2023 | 100 | 0.050 |
Why?
| Sound Spectrography | 1 | 2002 | 19 | 0.050 |
Why?
| Speech Acoustics | 1 | 2002 | 12 | 0.050 |
Why?
| Ischemia | 1 | 2006 | 405 | 0.050 |
Why?
| Serine | 1 | 2023 | 137 | 0.050 |
Why?
| Locomotion | 1 | 2003 | 100 | 0.050 |
Why?
| Glycine | 1 | 2023 | 166 | 0.050 |
Why?
| Vascular Endothelial Growth Factors | 1 | 2022 | 78 | 0.050 |
Why?
| Muscle Fatigue | 2 | 2001 | 101 | 0.050 |
Why?
| Cesarean Section | 1 | 2023 | 183 | 0.050 |
Why?
| Partial Pressure | 1 | 2001 | 30 | 0.050 |
Why?
| Blood Glucose | 3 | 2001 | 2103 | 0.050 |
Why?
| Species Specificity | 1 | 2003 | 568 | 0.050 |
Why?
| Anaerobic Threshold | 1 | 2001 | 28 | 0.050 |
Why?
| Health Education | 1 | 2005 | 335 | 0.050 |
Why?
| Plethysmography | 1 | 2001 | 106 | 0.050 |
Why?
| C-Peptide | 2 | 2001 | 163 | 0.050 |
Why?
| Veins | 1 | 2001 | 60 | 0.050 |
Why?
| Pyruvic Acid | 1 | 2021 | 53 | 0.050 |
Why?
| Forearm | 1 | 2001 | 117 | 0.050 |
Why?
| Insulin | 3 | 2001 | 2330 | 0.040 |
Why?
| Disease Susceptibility | 1 | 2003 | 334 | 0.040 |
Why?
| Ventricular Pressure | 1 | 2021 | 45 | 0.040 |
Why?
| Risk Assessment | 1 | 2010 | 3269 | 0.040 |
Why?
| Hyperbaric Oxygenation | 1 | 2021 | 39 | 0.040 |
Why?
| Genetic Variation | 1 | 2006 | 937 | 0.040 |
Why?
| Stress, Mechanical | 1 | 2002 | 467 | 0.040 |
Why?
| Posture | 1 | 2001 | 175 | 0.040 |
Why?
| Thoracic Arteries | 1 | 2000 | 4 | 0.040 |
Why?
| Exons | 1 | 2002 | 341 | 0.040 |
Why?
| Arginine | 1 | 2002 | 262 | 0.040 |
Why?
| Muscle, Skeletal | 2 | 2001 | 1644 | 0.040 |
Why?
| Asia | 1 | 2000 | 58 | 0.040 |
Why?
| Tonometry, Ocular | 1 | 2000 | 89 | 0.040 |
Why?
| Bromodeoxyuridine | 1 | 2000 | 78 | 0.040 |
Why?
| Adenosine Triphosphate | 1 | 2022 | 482 | 0.040 |
Why?
| Muscle Contraction | 2 | 2001 | 423 | 0.040 |
Why?
| Cross-Over Studies | 1 | 2002 | 521 | 0.040 |
Why?
| Paleontology | 1 | 2000 | 20 | 0.040 |
Why?
| Fetal Weight | 1 | 2000 | 55 | 0.040 |
Why?
| Linguistics | 1 | 2000 | 28 | 0.040 |
Why?
| Archaeology | 1 | 2000 | 34 | 0.040 |
Why?
| Geographic Mapping | 1 | 2019 | 21 | 0.040 |
Why?
| Endothelium | 1 | 2000 | 121 | 0.040 |
Why?
| Carbon Dioxide | 1 | 2001 | 260 | 0.040 |
Why?
| North America | 1 | 2000 | 294 | 0.040 |
Why?
| Organ Size | 1 | 2000 | 456 | 0.040 |
Why?
| Thiazolidinediones | 1 | 2020 | 137 | 0.040 |
Why?
| Litter Size | 1 | 1998 | 17 | 0.040 |
Why?
| Potassium Channel Blockers | 1 | 1998 | 36 | 0.040 |
Why?
| Ventricular Function, Right | 1 | 2021 | 276 | 0.040 |
Why?
| Cell Division | 1 | 2000 | 790 | 0.040 |
Why?
| Gene Expression | 1 | 2023 | 1465 | 0.040 |
Why?
| Cells, Cultured | 1 | 2006 | 4102 | 0.040 |
Why?
| Hormones | 1 | 1998 | 140 | 0.040 |
Why?
| Carotid Sinus | 1 | 1997 | 2 | 0.040 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 399 | 0.040 |
Why?
| Adrenal Glands | 1 | 1998 | 70 | 0.040 |
Why?
| Dietary Supplements | 1 | 2002 | 532 | 0.040 |
Why?
| Glucagon | 1 | 2018 | 105 | 0.040 |
Why?
| Embryo, Mammalian | 1 | 2018 | 224 | 0.040 |
Why?
| Hypertrophy, Right Ventricular | 1 | 1998 | 145 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 1 | 2002 | 2016 | 0.040 |
Why?
| Sensitivity and Specificity | 1 | 2002 | 1847 | 0.040 |
Why?
| Genome-Wide Association Study | 2 | 2017 | 1326 | 0.030 |
Why?
| Infusions, Intravenous | 1 | 1998 | 402 | 0.030 |
Why?
| Chemoreceptor Cells | 1 | 1997 | 54 | 0.030 |
Why?
| Cats | 1 | 1997 | 207 | 0.030 |
Why?
| Glomerular Filtration Rate | 2 | 1998 | 711 | 0.030 |
Why?
| China | 1 | 1997 | 192 | 0.030 |
Why?
| Glucose Tolerance Test | 1 | 2018 | 355 | 0.030 |
Why?
| Cell Cycle Proteins | 1 | 2021 | 583 | 0.030 |
Why?
| Ferritins | 1 | 2017 | 58 | 0.030 |
Why?
| Energy Intake | 1 | 2000 | 462 | 0.030 |
Why?
| Child, Preschool | 2 | 2015 | 10522 | 0.030 |
Why?
| Phosphorylation | 1 | 2021 | 1716 | 0.030 |
Why?
| Immunohistochemistry | 1 | 2020 | 1690 | 0.030 |
Why?
| California | 1 | 2017 | 400 | 0.030 |
Why?
| Renin-Angiotensin System | 2 | 2010 | 82 | 0.030 |
Why?
| Anesthesia | 1 | 1997 | 172 | 0.030 |
Why?
| Pulmonary Veins | 1 | 2015 | 98 | 0.030 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 836 | 0.030 |
Why?
| Energy Metabolism | 1 | 2000 | 875 | 0.030 |
Why?
| Aged | 2 | 2017 | 22107 | 0.030 |
Why?
| Leukocytes, Mononuclear | 1 | 2015 | 546 | 0.030 |
Why?
| Latin America | 1 | 2012 | 87 | 0.020 |
Why?
| Amino Acid Substitution | 1 | 2012 | 284 | 0.020 |
Why?
| Epigenesis, Genetic | 1 | 2015 | 615 | 0.020 |
Why?
| Globins | 1 | 2010 | 21 | 0.020 |
Why?
| Procollagen-Proline Dioxygenase | 1 | 2010 | 21 | 0.020 |
Why?
| Socioeconomic Factors | 1 | 2015 | 1214 | 0.020 |
Why?
| Thumb | 2 | 2001 | 26 | 0.020 |
Why?
| DNA Copy Number Variations | 1 | 2010 | 167 | 0.020 |
Why?
| Sequence Analysis, DNA | 1 | 2012 | 778 | 0.020 |
Why?
| Hydrocortisone | 2 | 2002 | 306 | 0.020 |
Why?
| Prognosis | 1 | 2017 | 3773 | 0.020 |
Why?
| Cyclic GMP | 2 | 1998 | 90 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2017 | 4896 | 0.020 |
Why?
| Aging | 1 | 1998 | 1774 | 0.020 |
Why?
| Indians, Central American | 1 | 2007 | 5 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 2012 | 2833 | 0.020 |
Why?
| Chromosomes, Human | 1 | 2007 | 41 | 0.020 |
Why?
| Genetic Linkage | 1 | 2007 | 296 | 0.020 |
Why?
| Aged, 80 and over | 1 | 2017 | 7066 | 0.020 |
Why?
| Biomarkers | 1 | 2017 | 3971 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 756 | 0.010 |
Why?
| Cell Line, Tumor | 1 | 2012 | 3185 | 0.010 |
Why?
| Heart Failure | 1 | 2017 | 2148 | 0.010 |
Why?
| International Cooperation | 1 | 2005 | 177 | 0.010 |
Why?
| Genetic Testing | 1 | 2007 | 422 | 0.010 |
Why?
| Tilt-Table Test | 1 | 2001 | 8 | 0.010 |
Why?
| Placebos | 1 | 2001 | 201 | 0.010 |
Why?
| Societies, Medical | 1 | 2005 | 759 | 0.010 |
Why?
| Dietary Carbohydrates | 1 | 2001 | 152 | 0.010 |
Why?
| Transducers, Pressure | 1 | 1999 | 13 | 0.010 |
Why?
| Water-Electrolyte Balance | 1 | 2000 | 34 | 0.010 |
Why?
| Fasting | 1 | 2001 | 268 | 0.010 |
Why?
| Electric Stimulation | 1 | 1999 | 269 | 0.010 |
Why?
| Nitrogen | 1 | 2000 | 162 | 0.010 |
Why?
| Electrolytes | 1 | 1998 | 59 | 0.010 |
Why?
| Pregnancy Trimester, First | 1 | 1998 | 137 | 0.010 |
Why?
| Renin | 1 | 1997 | 32 | 0.010 |
Why?
| Atrial Natriuretic Factor | 1 | 1997 | 56 | 0.010 |
Why?
| Aldosterone | 1 | 1997 | 43 | 0.010 |
Why?
| Bicarbonates | 1 | 1997 | 42 | 0.010 |
Why?
| Nitrites | 1 | 1997 | 83 | 0.010 |
Why?
| Nitrates | 1 | 1997 | 88 | 0.010 |
Why?
| Chlorides | 1 | 1997 | 139 | 0.010 |
Why?
| Cyclic AMP | 1 | 1997 | 238 | 0.010 |
Why?
| Sodium | 1 | 1997 | 205 | 0.010 |
Why?
| Oxidation-Reduction | 1 | 2000 | 1031 | 0.010 |
Why?
| Body Composition | 1 | 2000 | 649 | 0.010 |
Why?
| Poverty | 1 | 1999 | 499 | 0.010 |
Why?
| Insulin Resistance | 1 | 2001 | 1168 | 0.010 |
Why?
|
|
Moore's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|